Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. The company's marketed vaccines include 13-valent pneumococcal polysaccharide conjugate vaccine, varicella vaccine, freeze-dried, hepatitis B vaccine, inflammatory vaccine, 23-valent pneumococcal polysaccharide vaccine, DTAP/HIB combined vaccine, diphtheria, tetanu… Read more
Shenzhen Kangtai Biological Products Co Ltd (300601) - Total Liabilities
Latest total liabilities as of September 2025: CN¥4.52 Billion CNY
Based on the latest financial reports, Shenzhen Kangtai Biological Products Co Ltd (300601) has total liabilities worth CN¥4.52 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shenzhen Kangtai Biological Products Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Shenzhen Kangtai Biological Products Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shenzhen Kangtai Biological Products Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Kangtai Biological Products Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bodycote plc
PINK:BYPLF
|
USA | $406.70 Million |
|
Sanxiang Advanced Materials
SHG:603663
|
China | CN¥743.18 Million |
|
Sezzle Inc.
NASDAQ:SEZL
|
USA | $211.69 Million |
|
KLCC Property Holdings Bhd
KLSE:5235SS
|
Malaysia | RM5.06 Billion |
|
China Railway Hi-tech Industry Corp Ltd
SHG:600528
|
China | CN¥37.95 Billion |
|
Sichuan Rongda Gold Co. Ltd. Cl A
SHE:001337
|
China | CN¥557.91 Million |
|
Nuscale Power Corp
NYSE:SMR
|
USA | $448.32 Million |
|
Port of Tauranga Limited
OTCGREY:PTAUF
|
USA | $717.00 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Shenzhen Kangtai Biological Products Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Kangtai Biological Products Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Kangtai Biological Products Co Ltd (2012–2024)
The table below shows the annual total liabilities of Shenzhen Kangtai Biological Products Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥4.90 Billion | -11.56% |
| 2023-12-31 | CN¥5.54 Billion | +15.47% |
| 2022-12-31 | CN¥4.80 Billion | -3.64% |
| 2021-12-31 | CN¥4.98 Billion | +134.89% |
| 2020-12-31 | CN¥2.12 Billion | +77.03% |
| 2019-12-31 | CN¥1.20 Billion | -20.32% |
| 2018-12-31 | CN¥1.50 Billion | +31.93% |
| 2017-12-31 | CN¥1.14 Billion | +31.62% |
| 2016-12-31 | CN¥865.90 Million | +26.09% |
| 2015-12-31 | CN¥686.71 Million | -9.44% |
| 2014-12-31 | CN¥758.25 Million | +3.20% |
| 2013-12-31 | CN¥734.74 Million | +4.14% |
| 2012-12-31 | CN¥705.50 Million | -- |